Tolerance development of 8α,9α- and 8β,9β- epoxyhexahydrocannabinols in the mouse

S. Narimatsu, K. Watanabe, I. Yamamoto, H. Yoshimura

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Seven daily administrations of 8α,9α- and 8β,9β-epoxyhexahydrocannabinols (EHHCs) (10 mg/kg, i.v. and 5 mq/kg, i.v., respectively, once a day) developed tolerance to their pharmacological effects such as hypothermia, catalepsy and pentobarbital-induced sleep prolongation in the mouse. Comparing with the effect obtained on the 1st day, the significant reduction was observed on the 3rd to 4th day of EHHCs treatments. Tolerant mice received EHHCs for 3 consecutive days showed cross-tolerance to Δ8-tetrahydrocannabinol (THC) in all the pharmacological indices. Furthermore, EHHCs-tolerant mice were also cross-tolerant to hypothermic effect of chlorpromazine. On the other hand, 8β,9β-EHHC-tolerant, but not 8α,9α-EHHC-tolerant mice showed cross-tolerance to hypothermia induced with morphine. These results suggest that both epoxides may contribute to the tolerance development to Δ8-THC as active metabolites at least in part.

Original languageEnglish
Pages (from-to)301-314
Number of pages14
JournalResearch Communications in Substances of Abuse
Issue number4
Publication statusPublished - Jan 1 1983

ASJC Scopus subject areas

  • Medicine (miscellaneous)


Dive into the research topics of 'Tolerance development of 8α,9α- and 8β,9β- epoxyhexahydrocannabinols in the mouse'. Together they form a unique fingerprint.

Cite this